Published in PLoS One on March 29, 2010
Cancer statistics, 2005. CA Cancer J Clin (2005) 25.65
Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res (1994) 4.32
Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res (2000) 3.71
A microtomographic system for the nondestructive evaluation of bone architecture. Calcif Tissue Int (1996) 2.98
The direct examination of three-dimensional bone architecture in vitro by computed tomography. J Bone Miner Res (1989) 2.89
Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci U S A (2008) 2.47
Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. Int J Cancer (1998) 2.36
Morphometric analysis of human bone biopsies: a quantitative structural comparison of histological sections and micro-computed tomography. Bone (1998) 2.18
Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst (2003) 2.16
Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res (1997) 2.02
Spread of prostatic cancer to bone. Urology (1983) 1.94
Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. Prostate (2002) 1.78
Analysis of emission tomographic scan data: limitations imposed by resolution and background. J Comput Assist Tomogr (1984) 1.75
Ovariectomy-induced bone loss varies among inbred strains of mice. J Bone Miner Res (2005) 1.70
An in vivo mouse model for human prostate cancer metastasis. Neoplasia (2008) 1.54
Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Res (1999) 1.48
A fluorescent orthotopic bone metastasis model of human prostate cancer. Cancer Res (1999) 1.46
Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res (2003) 1.42
Cancer gene therapy using mesenchymal stem cells expressing interferon-beta in a mouse prostate cancer lung metastasis model. Gene Ther (2008) 1.42
A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. J Natl Cancer Inst (2007) 1.41
Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue. Am J Pathol (2005) 1.32
Volumetric quantitative CT of the spine and hip derived from contrast-enhanced MDCT: conversion factors. AJR Am J Roentgenol (2007) 1.12
Growth factors to stimulate bone formation. J Bone Miner Res (1993) 1.11
Micro-CT examinations of trabecular bone samples at different resolutions: 14, 7 and 2 micron level. Technol Health Care (1998) 1.09
Establishment of human prostate carcinoma skeletal metastasis models. Cancer (2000) 1.07
In vivo, three-dimensional microscopy of trabecular bone. J Bone Miner Res (1995) 1.07
A morphometric comparison of trabecular structure of human ilium between microcomputed tomography and conventional histomorphometry. Calcif Tissue Int (1997) 1.03
Advances in mouse models of prostate cancer. Expert Rev Mol Med (2008) 1.01
High-resolution three-dimensional micro-computed tomography detects bone loss and changes in trabecular architecture early: comparison with DEXA and bone histomorphometry in a rat model of disuse osteoporosis. Invest Radiol (2002) 1.00
Human prostate cancer expresses the low affinity insulin-like growth factor binding protein IGFBP-rP1. Cancer Res (1999) 0.99
In vivo imaging of prostate cancer involving bone in a mouse model. Prostate (2007) 0.89
Spiculated periosteal response induced by intraosseous injection of 22Rv1 prostate cancer cells resembles subset of bone metastases in prostate cancer patients. Prostate (2005) 0.87
Intraosseous growth of human prostate cancer in implanted adult human bone: relationship of prostate cancer cells to osteoclasts in osteoblastic metastatic lesions. Prostate (2004) 0.84
Trabecular thickness measurement in cancellous bones: postmortem rat studies with the zoom-in micro-tomography technique. Physiol Meas (2005) 0.82
TabBO: a model reflecting common molecular features of androgen-independent prostate cancer. Clin Cancer Res (2000) 0.77
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood (2008) 6.39
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med (2006) 6.18
Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell (2006) 4.13
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol (2005) 4.06
Steps toward mapping the human vasculature by phage display. Nat Med (2002) 3.82
A role for uric acid in the progression of renal disease. J Am Soc Nephrol (2002) 3.77
Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell (2011) 3.53
Simplified staging for hepatocellular carcinoma. J Clin Oncol (2002) 3.48
CT dose index and patient dose: they are not the same thing. Radiology (2011) 3.38
Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol (2002) 3.37
Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol (2002) 3.32
Regulation of tumor angiogenesis by EZH2. Cancer Cell (2010) 3.10
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood (2007) 2.91
Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol (2007) 2.77
A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol (2012) 2.77
Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol (2010) 2.71
Description and implementation of a quality control program in an imaging-based clinical trial. Acad Radiol (2006) 2.71
Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res (2011) 2.64
Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol (2008) 2.53
Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. J Clin Oncol (2012) 2.48
A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol (2008) 2.39
Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst (2009) 2.34
A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res (2008) 2.30
Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res (2007) 2.28
Body surface area and body weight predict total liver volume in Western adults. Liver Transpl (2002) 2.21
Biological consequences of tightly bent DNA: the other life of a macromolecular celebrity. Biopolymers (2007) 2.19
Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype. Clin Cancer Res (2011) 2.15
Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res (2008) 2.15
Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res (2005) 2.14
PBI-05204, a supercritical CO₂ extract of Nerium oleander, inhibits growth of human pancreatic cancer via targeting the PI3K/mTOR pathway. Invest New Drugs (2014) 2.04
Emergence and persistence of CXCR4-tropic HIV-1 in a population of men from the multicenter AIDS cohort study. J Infect Dis (2008) 2.01
Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras. Cancer Res (2005) 2.01
The feasibility of a scanner-independent technique to estimate organ dose from MDCT scans: using CTDIvol to account for differences between scanners. Med Phys (2010) 1.97
Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol (2011) 1.96
A method to generate equivalent energy spectra and filtration models based on measurement for multidetector CT Monte Carlo dosimetry simulations. Med Phys (2009) 1.94
High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. Cancer Res (2005) 1.94
Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest (2008) 1.87
In vivo respiratory-gated micro-CT imaging in small-animal oncology models. Mol Imaging (2004) 1.85
High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. Cancer Res (2006) 1.84
PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res (2012) 1.83
Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J Clin Oncol (2004) 1.83
Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol Cancer Ther (2011) 1.81
A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res (2008) 1.80
The feasibility of patient size-corrected, scanner-independent organ dose estimates for abdominal CT exams. Med Phys (2011) 1.77
Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. Leuk Lymphoma (2014) 1.77
A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci Transl Med (2011) 1.74
Monte Carlo simulations to assess the effects of tube current modulation on breast dose for multidetector CT. Phys Med Biol (2009) 1.70
The current state of preclinical prostate cancer animal models. Prostate (2008) 1.68
Activation of β-catenin signaling in androgen receptor-negative prostate cancer cells. Clin Cancer Res (2012) 1.68
Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol (2009) 1.68
Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol (2006) 1.67
Surgical treatment of multivalvular endocarditis: twenty-one-year single center experience. J Thorac Cardiovasc Surg (2009) 1.66
Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol (2011) 1.65
Synchronous selection of homing peptides for multiple tissues by in vivo phage display. FASEB J (2006) 1.63
Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes. BJU Int (2013) 1.63
The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin Cancer Res (2008) 1.62
Repeat endoscopic ultrasound-guided fine needle aspiration for solid pancreatic lesions at a tertiary referral center will alter the initial inconclusive result. J Gastrointestin Liver Dis (2013) 1.62
Downregulation of LRIG2 expression by RNA interference inhibits glioblastoma cell (GL15) growth, causes cell cycle redistribution, increases cell apoptosis and enhances cell adhesion and invasion in vitro. Cancer Biol Ther (2009) 1.60
Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b. Prostate (2012) 1.53
Radiation dose to the fetus for pregnant patients undergoing multidetector CT imaging: Monte Carlo simulations estimating fetal dose for a range of gestational age and patient size. Radiology (2008) 1.53
Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol (2006) 1.52
Association and interactions between DNA repair gene polymorphisms and adult glioma. Cancer Epidemiol Biomarkers Prev (2009) 1.51
Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res (2011) 1.48
Nanotopography influences adhesion, spreading, and self-renewal of human embryonic stem cells. ACS Nano (2012) 1.47
miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. Cancer Res (2013) 1.46
Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Clin Cancer Res (2012) 1.44
Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res (2007) 1.42
Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res (2003) 1.42
Compressive nanomechanics of opposing aggrecan macromolecules. J Biomech (2005) 1.41
Dose to radiosensitive organs during routine chest CT: effects of tube current modulation. AJR Am J Roentgenol (2009) 1.41
Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol (2008) 1.40
A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patients. Cancer J (2014) 1.40
Selective left subclavian ligation in total aortic arch replacement. Ann Thorac Surg (2011) 1.40
Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor. Leuk Lymphoma (2014) 1.40
Treatment outcomes of small cell carcinoma of the prostate: a single-center study. Cancer (2007) 1.39
Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. J Natl Cancer Inst (2006) 1.39
A local risk prediction model for prolonged ventilation after adult heart valve surgery in a Chinese single center. Heart Lung (2012) 1.37
Real-time observations of single bacteriophage lambda DNA ejections in vitro. Proc Natl Acad Sci U S A (2007) 1.35
Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res (Phila) (2010) 1.35
Preoperative predictors of survival after resection of small hepatocellular carcinomas. Ann Surg (2002) 1.35
Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. Am J Nephrol (2005) 1.33
A Bayesian semiparametric survival model with longitudinal markers. Biometrics (2009) 1.29
Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts. Neoplasia (2007) 1.29
Diffusion-weighted MRI in the detection of prostate cancer: meta-analysis. AJR Am J Roentgenol (2012) 1.28
Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol (2009) 1.27
Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer (2004) 1.27
Ability of integrated positron emission and computed tomography to detect significant colonic pathology: the experience of a tertiary cancer center. Cancer (2010) 1.25
Bayesian ensemble methods for survival prediction in gene expression data. Bioinformatics (2010) 1.24
Adipose tissue-derived stem cells promote prostate tumor growth. Prostate (2010) 1.22
Understanding the biology of bone metastases: key to the effective treatment of prostate cancer. Clin Cancer Res (2008) 1.22
Relationship between epidemiologic risk factors and breast cancer recurrence. J Clin Oncol (2007) 1.21
Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancer. Mol Cancer Ther (2010) 1.21
Ensuring the radiologist workforce: opportunities during education. J Am Coll Radiol (2004) 1.20
The 3p21.3 tumor suppressor NPRL2 plays an important role in cisplatin-induced resistance in human non-small-cell lung cancer cells. Cancer Res (2006) 1.19
Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. Cancer (2011) 1.19
Nanowire substrate-based laser scanning cytometry for quantitation of circulating tumor cells. Nano Lett (2012) 1.19